ASCO口头报告信达生物公布IBI343(创新型抗CLDN18.2 ADC)治疗晚期胰腺癌的I期临床研究数据更新

动脉网
Jun 03, 2025

信达生物在2025年ASCO年会上公布,其创新型药物IBI343在治疗CLDN18.2表达阳性的晚期胰腺癌患者中展现出优秀治疗潜力,已获NMPA和FDA认定。最新研究数据显示,该药物在83例胰腺癌患者中表现出良好的疗效和安全性。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10